Fortress Biotech, Inc. FBIOP

Full chart Compare
Set alert

Price alert · FBIOP

All alert types
14.91 USD +0.14 (+0.95%)

At closeNov 3, 2026, 4:00 PM EST

14.77 -0.14 -0.94%

After hours · Nov 3, 4:00 PM ET

14.25 Day range 15.20
6.27 52-week range 21.43
YTD
+57.11%
1 year
+113.61%
Market cap
35.16M
Revenue (ttm)
82.62M
Profit margin
-49.25%
EPS (ttm)
-0.863
Shares out
56.68M
Dividend
2.34 (45.96%)
Ex-dividend date
Jun 13, 2024
YTD return
+57.11%
1-year return
+113.61%
Volume
33.73K
Avg volume
12.52K
Open
14.85
Previous close
14.77
Day's range
14.25 – 15.20
52-week range
6.27 – 21.43
Beta
1.75

3M -4.00 (-21.15%)

161820Aug 12Aug 31Sep 18Oct 7Oct 2614.91

Key statistics

Enterprise value
96.10M
PEG ratio
0.00
Price / sales
0.43
Price / book
4.39
Dividend yield
45.96%
Payout ratio
0.00%
Revenue growth
-14.30%
Free cash flow
-59.20M
Total cash
76.20M
Total debt
88.42M
Return on equity
0.00%
Short % of float
0.00%
50-day average
5.83
200-day average
10.33

Next earnings

Consensus EPS estimate 0.00.

Earnings history

About Fortress Biotech, Inc.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on FBIOP — it syncs with the Stock Master app.

Insider holders

FBIOP insider holders
InsiderRelationLatest transactionDateShares held
JIN DAVIDChief Financial OfficerPurchaseJul 9, 2024500
ROSENWALD LINDSAY AChief Executive OfficerPurchaseJul 10, 2024127,500

Institution ownership

FBIOP institution ownership
Holder% heldSharesValueReported
Shikiar Asset Management, Inc.0.44%15,00098.25KJun 29, 2023